Yon-Dschun Ko
Overview
Explore the profile of Yon-Dschun Ko including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
126
Citations
6555
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hoppe R, Winter S, Lo W, Michailidou K, Bolla M, Keeman R, et al.
NPJ Breast Cancer
. 2025 Feb;
11(1):18.
PMID: 39971965
The role of germline genetics in adjuvant aromatase inhibitor (AI) treatment efficacy in ER-positive breast cancer is poorly understood. We employed a two-stage candidate gene approach to examine associations between...
2.
Leypoldt L, Tichy D, Besemer B, Hanel M, Raab M, Mann C, et al.
Future Oncol
. 2024 Sep;
20(39):3193-3207.
PMID: 39345094
No abstract available.
3.
Zanti M, OMahony D, Parsons M, Dorling L, Dennis J, Boddicker N, et al.
medRxiv
. 2024 Sep;
PMID: 39281752
Clinical genetic testing identifies variants causal for hereditary cancer, information that is used for risk assessment and clinical management. Unfortunately, some variants identified are of uncertain clinical significance (VUS), complicating...
4.
Marinova M, Khouri D, Kuppers J, Ramig O, Strunk H, Breuers J, et al.
J Clin Med
. 2024 Jul;
13(13).
PMID: 38999283
Background: Pancreatic adenocarcinoma (PaC) still has a dismal prognosis, and despite medical advances, a bleak 5-year survival rate of only 8%, largely due to late diagnosis and limited curative surgical...
5.
George J, Maas L, Abedpour N, Cartolano M, Kaiser L, Fischer R, et al.
Nature
. 2024 Mar;
627(8005):880-889.
PMID: 38480884
The evolutionary processes that underlie the marked sensitivity of small cell lung cancer (SCLC) to chemotherapy and rapid relapse are unknown. Here we determined tumour phylogenies at diagnosis and throughout...
6.
Brik A, Wichert K, Weber D, Szafranski K, Rozynek P, Meier S, et al.
BMC Res Notes
. 2023 Oct;
16(1):279.
PMID: 37858127
Objective: Lung cancer is the second most frequent cancer type and the most common cause of cancer-related deaths worldwide. Alteration of gene copy numbers are associated with lung cancer and...
7.
Wichert K, Hoppe R, Ickstadt K, Behrens T, Winter S, Herold R, et al.
Eur J Epidemiol
. 2023 Oct;
38(10):1053-1068.
PMID: 37789226
Light-at-night triggers the decline of pineal gland melatonin biosynthesis and secretion and is an IARC-classified probable breast-cancer risk factor. We applied a large-scale molecular epidemiology approach to shed light on...
8.
Leypoldt L, Tichy D, Besemer B, Hanel M, Raab M, Mann C, et al.
J Clin Oncol
. 2023 Sep;
42(1):26-37.
PMID: 37753960
Purpose: The GMMG-CONCEPT trial investigated isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in transplant-eligible (TE) and transplant-noneligible (TNE) patients with newly diagnosed multiple myeloma (NDMM) with exclusively high-risk disease for whom...
9.
Middha P, Wang X, Behrens S, Bolla M, Wang Q, Dennis J, et al.
Breast Cancer Res
. 2023 Aug;
25(1):93.
PMID: 37559094
Background: Genome-wide studies of gene-environment interactions (G×E) may identify variants associated with disease risk in conjunction with lifestyle/environmental exposures. We conducted a genome-wide G×E analysis of ~ 7.6 million common...
10.
Gunther M, Hentschel L, Schuler M, Muller T, Schutte K, Ko Y, et al.
BMC Cancer
. 2023 Jul;
23(1):629.
PMID: 37407982
Background: To include the patient perspective in the assessment of adverse events in oncology, a patient-reported outcomes (PRO) version of the Common Terminology Criteria for Adverse Events (CTCAE) was developed...